Education
About Us
Working with TipRanks
Follow Us
uniQure N.V. (QURE)
NASDAQ:QURE
Earnings Data
Report Date
May 12, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.89Last Year’s EPS
-0.82Same Quarter Last Year
Moderate Buy
Based on 12 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call communicated major positive clinical advances (notably strong 3‑year AMT‑130 efficacy, supportive Fabry and TLE data) and a strengthened balance sheet, but these were tempered by significant regulatory resistance from the FDA (recommendation for a sham‑controlled Phase III), safety‑related pauses/holds in two programs (AMT‑191 dosing pause and AMT‑162 hold), and a substantial year‑over‑year revenue decline. Management emphasized active regulatory engagement, continued data generation (4‑year AMT‑130 analysis) and pursuit of ex‑U.S. pathways and early access options, while acknowledging material uncertainty around Phase III design, cost and feasibility.Company Guidance
AMT-130: Robust 3‑Year Clinical Efficacy
Phase I/II 3‑year data demonstrated a statistically significant 75% slowing of disease progression on the composite UHDRS and a 60% slowing on Total Functional Capacity versus an external Enroll HD comparator; reduction in neurofilament light and supportive trends across other clinically meaningful endpoints. Company plans a 4‑year analysis in Q3 2026 and intends to amend the SAP and submit the analysis to regulators.
AMT-191 (Fabry): Durable Enzyme Activity and ERT Withdrawal
Preliminary Phase I/II data from 11 patients showed dose‑dependent elevation in alpha‑Gal A enzyme activity durable from 4 months up to >1 year; as of the call all 11 patients have been withdrawn from enzyme replacement therapy.
AMT-260 (Temporal Lobe Epilepsy): Early Promising Signals
Case study of first patient with up to 6 months follow‑up showed a promising reduction in seizure frequency and no serious adverse events; enrollment completed for five additional patients in cohort 1 (six total) with cohort 2 enrollment underway and a planned Q2 update on six patients with ≥6 months follow‑up.
Strong Cash Position and Capital Raise
Cash, cash equivalents and investment securities totaled $622.5 million at Dec 31, 2025 vs $367.5 million at Dec 31, 2024, an increase of ~$255.0 million (+69.4%), primarily from ~$404.2 million in proceeds from public offerings and prefunded loans; company expects cash to fund operations into the second half of 2026.
Operational Efficiency from Divestiture
Cost of contract manufacturing revenues was nil in 2025 versus $17.1 million in 2024 following the 2024 divestiture of the Lexington manufacturing facility; R&D 'other' costs decreased by $26.0 million driven by lower employee/contractor/severance and facility costs.
Regulatory Engagement and Global Pathway Strategy
Company is actively engaging the FDA (Type B planned for Q2 2026), pursuing dialogue with ex‑U.S. regulators (MHRA, EMA and others), and evaluating named‑patient/early access programs and ex‑U.S. regulatory pathways to accelerate patient access.
Strong Community and KOL Support
Broad advocacy from the Huntington's disease community and positive feedback from neurosurgeons, neurologists and HD centers of excellence reinforce clinical interest and urgency for regulatory flexibility and access.
QURE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
QURE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 02, 2026 | $15.63 | $10.50 | -32.82% |
Nov 10, 2025 | $27.79 | $26.15 | -5.90% |
Jul 29, 2025 | $14.98 | $13.68 | -8.68% |
May 09, 2025 | $12.25 | $12.79 | +4.41% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does uniQure N.V. (QURE) report earnings?
uniQure N.V. (QURE) is schdueled to report earning on May 12, 2026, TBA (Confirmed).
What is uniQure N.V. (QURE) earnings time?
uniQure N.V. (QURE) earnings time is at May 12, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is QURE EPS forecast?
QURE EPS forecast for the fiscal quarter 2026 (Q1) is -0.89.